Lyophilized Injectable Drugs Market

Global Lyophilized Injectable Drugs Market  is valued at USD 3.11 Billion in 2022 and is expected to reach USD 4.88 Billion by 2029 with a CAGR of 6.6% over the forecast period.

Global Lyophilized Injectable Drugs Market: Global Size, Trends, Competitive, and Historical & Forecast Analysis, 2022-2029: Rising Regulatory Approvals for Lyophilized Drugs and increasing  Initiatives Such as Product Launches and Acquisitions by Major Businesses for the Advancement & Distribution of Anesthetics to Various Healthcare-Giving Organizations are some of the major factors driving the growth of the Lyophilized Injectable Drugs Market

Scope-

Lyophilized injectables are freeze-dried drugs that are stable during transportation. They are kept for a longer time in customized packaging, point-of-care reconstitution, and single-use vials. Solvents can be used to reconstitute the necessary amount of medications at the time of usage. Since they are produced via the lyophilization process, which is a method of separating a solid substance from a solvent by freezing and evaporating the solution under a vacuum, lyophilized injectables are also known as freeze-dried injectables. Injections that have been lyophilized are frequently regarded as the best option for oral solid dose forms.

In several case studies, people who were confined to beds benefited significantly from the injections. Since lyophilized injections have a longer shelf life than other dosage forms, they are also recommended for patients with a variety of conditions to achieve maximum bioavailability and stability.

COVID-19 Impact-

Medical supplies were in high   demand during the pandemic era as a result of the afflicted population. Some of the support devices utilized include different single-step devices, multi-step devices, prefilled diluent syringes, and specialized reconstitution devices. Additionally, COVID-19 has caused a significant increase in demand for medical supplies such as masks, gloves, and protective eyewear. There is a growing demand for medical supplies from both healthcare professionals and the general public as a result of an increase in COVID-19 cases across the world.

The producers of these products have an opportunity to benefit from the rise in demand for medical supplies in order to provide a sufficient and ongoing supply of personal protective equipment in the market for lyophilized injectable pharmaceuticals. Due to these factors, COVID-19 is anticipated to have a substantial effect on the market for lyophilized injectable drugs.

Key Players-

The prominent players operating in this marketplace are -

• Avaya Inc.
• Alcatel Lucent Enterprise
• Cisco Systems Inc
• Five9 Inc.
• Unify Inc
• Enghouse Interactive Inc.
• Microsoft Corporation
• Genesys
• SAP SE
• NICE inContact
• others

Segmentation-

By Drug:

• Anti-infective
• Anti-neoplastic
• Anticoagulant
• Hormones
• Antiarrhythmic
• Others

By Indication:

• Autoimmune Diseases
• Respiratory Diseases
• Gastrointestinal Disorders
• Oncology
• Cardiovascular Diseases
• Infectious Diseases
• Metabolic Disorders
• Others

By Delivery:

• Prefilled Diluent Syringes
• Proprietary Reconstitution Devices
• Single-step Devices
• Multistep Devices

By Packaging:

• Single-use Vials
• Point of Care Reconstitution
• Specialty Packaging
• Others

By End User:

• Life Science Research
• Hospitals
• Specialty Clinics
• Others

By Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

By Regional & Country Level:

• North America

  • U.S.
  • Canada

• Europe

  • U.K.
  • France
  • Germany
  • Italy

• Asia Pacific

  • China
  • Japan
  • India
  • Southeast Asia

• Latin America

  • Brazil
  • Mexico

• Middle East and Africa

  • GCC
  • Africa
  • Rest of Middle East and Africa

Market Drivers-

Rising Regulatory Approvals for Lyophilized Drugs Is Expected to Boost Lyophilized Injectable Drugs Market Growth:

The market for lyophilized injectable drugs is anticipated to develop as a result of rising regulatory approvals for a number of lyophilized formulations intended to treat different illness conditions. For instance, Mylan received a regulatory license from DCGI in February 2020 to market Remdesivir as a lyophilized powder in India for a limited period of time only in COVID-19 patients.

Cipla introduced Cipremi, a lyophilized powder for injection of remdesivir, in June 2020. Additionally, Gilead Sciences Inc. received an Emergency Utilize Authorization (EUA) from the US FDA to use Remdesivir for COVID-19 patients who are hospitalized. For adult and pediatric hospitalized patients with suspected or laboratory-confirmed COVID-19 infection, it is the sole FDA-approved EUA therapy. As a result, in May, Gilead Sciences Inc. granted Cipla a voluntarily nonexclusive license to manufacture Cipla’s generic version of remedisvir called CIPREMI. As a result, in May, Gilead Sciences Inc. granted Cipla a voluntarily nonexclusive license to manufacture Cipla’s generic version of remedisvir called CIPREMI.

Jubilant Life was granted approval by the Drug Controller General of India (DCGI) in July 2020 to manufacture and sell Remdesivir for injection in lyophilized form, 100 mg/vial, for restricted emergency usage in India for the management of severe COVID-19.

Rising Initiatives Such as Product Launches and Acquisitions by Major Businesses for the Advancement and Distribution of Anesthetics to Various Healthcare-Giving Organizations are Expected to Accelerate Lyophilized Injectable Drugs Market Development:

Rising initiatives such as product launches and acquisitions by major businesses for the advancement and distribution of anesthetics to various healthcare-giving organizations are anticipated to boost the market in the coming year. For instance, in December 2018, Aisthesis Partners in Anesthetic Care and its affiliated medical practices ('Aisthesis') acquired some of its assets to North American Partners in Anesthesia (NAPA), a single-specialty anesthesia and perioperative management organization in the United States. 25 ambulatory surgery centers (ASCs), 3 hospitals, and 3 doctor's offices in four states and the District of Columbia get anesthetic services from Aisthesis. Thus, this approach is expected to increase the demand for lyophilized injectable drugs, which in turn is projected to drive the market in the coming year.

Market Restraints-

The Rising Number of Product Recalls for Lyophilized Drugs and Packaging Type is Expected to Hinder Lyophilized Injectable Drugs Market Growth:

The market for lyophilized injectable drugs may experience slower growth as a result of an increase in product recalls for both lyophilized drugs and their packaging. Three lots of Vecuronium Bromide for Injection, 10 mg (lyophilized powder), and one lot of Vecuronium Bromide for Injection, 20 mg (lyophilized powder), both manufactured by Sun Pharmaceutical Industries, Inc., were subject to a product recall notice from the U.S. Food and Drug Administration in January 2019. Due to the product's inclusion of glass particles, it has been recalled. This factor may be expected to hinder the market in the coming year.

Geography Analysis-

North America is expected to Capture a Major Share of the Global Lyophilized Injectable Drugs Market:

North America is predicted to experience profitable growth in the global market for lyophilized Injectable drugs owing to the rising frequency of illnesses in the U.S. The North American Lyophilized Drugs Market is expanding due to the presence of large manufacturers that are heavily involved in the production of lyophilized injectables, including Fresenius Kabi, Merck & Co. Inc., and Amneal Pharmaceutical. Additionally, regulatory agencies in North America are anticipated to approve more products, which will support market growth. For instance, Methylprednisolone Sodium Succinate Injection USP (a lyophilized medication), 40 mg/vial, 125 mg/vial, 500 mg/vial, and 2 g/vial got FDA clearance in December 2015 from Aurobindo Pharma Limited.

Asia Pacific Lyophilized Injectable Drugs Market Is Expected to Grow at A Considerable Pace Over the Forecast Period:

Asia Pacific is also anticipated to propel the growth of the global lyophilized drugs market due to initiatives taken by major companies to expand their production facilities in order to produce lyophilized drugs on a big scale. For instance, the Indian pharmaceutical company Alembic Pharmaceuticals launched its new production plant in Panelav, Gujarat, in July 2017. The new facility can produce over 20 million liquid injectable and lyophilized concentration vials each year.

News-

• Zydus Cadila announced in March 2021 that the price of Remdac, a generic form of Remdesivir used for COVID-19 patients in India, has been decreased. The company's strategic decision has raised the demand for the product and sales in the market, increasing the company's credibility.

Report Analysis	Details
Historical data	2016 - 2021
Forecast Period	2022 - 2029
Market Size in 2022:	USD 3.11 Billion
Base year considered	2021
Forecast Period CAGR %:	6.6%
Market Size Expected in 2029:	USD 4.88 Billion
Tables, Charts & Figures:	175
Pages	300
Companies	Avaya, Inc., Alcatel Lucent Enterprise, Cisco Systems, Inc, Five9, Inc., Unify Inc, Enghouse Interactive Inc., Microsoft Corporation, Genesys, SAP SE, NICE inContact, and others
Segments Covered	By Drug, By Indication, By Delivery, By Packaging, By End User, By Distribution Channel
Regional Analysis	North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa